Objective neurocognitive functioning and neurocognitive complaints in patients with high-grade glioma: Evidence of cognitive awareness from the European Organisation for Research and Treatment of Cancer brain tumour clinical trials

Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial

(2018) Martin J van den Bent et al.   LANCET ONCOLOGY

Lomustine and Bevacizumab in Progressive Glioblastoma

(2017) Wolfgang Wick et al.   NEW ENGLAND JOURNAL OF MEDICINE

Impact of neurocognitive deficits on patient–proxy agreement regarding health-related quality of life in low-grade glioma patients

(2016) Divine E. Ediebah et al.   QUALITY OF LIFE RESEARCH

Mental incapacity in patients undergoing neuro-oncologic treatment: A cross-sectional study

(2014) S. Kerrigan et al.   NEUROLOGY

Screening for major depressive disorder in adults with glioma using the PHQ-9: a comparison of patient versus proxy reports

(2013) Alasdair Grant Rooney et al.   JOURNAL OF NEURO-ONCOLOGY

Congruence of primary brain tumor patient and caregiver symptom report

(2012) Terri S. Armstrong et al.   CANCER

Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab

(2011) J. S. Wefel et al.   NEURO-ONCOLOGY

The influence of cognitive impairment on health-related quality of life in neurological disease

(2010) Alex J. Mitchell et al.   ACTA NEUROPSYCHIATRICA

Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer

(2010) Jeffrey S. Wefel et al.   CANCER

Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up

(2009) Linda Douw et al.   LANCET NEUROLOGY